FindTrial
Sign In

IBI308

DRUG8 trials

Sponsors

Innovent Biologics (Suzhou) Co. Ltd., Taizhou Hospital, Sun Yat-sen University, Junling Li

Conditions

Acral Melanoma That Has Been Removed by SurgeryAdvanced/Metastatic Solid MalignanciesCancer, Solid TumorEsophageal Squamous Cell CarcinomaExtensive-Stage Small Cell Lung CancerLung Cancer Stage IIINon-small Cell Lung CancerThoracic Malignancies

Phase 1

First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors
CompletedNCT02937116
Innovent Biologics (Suzhou) Co. Ltd.Cancer, Solid Tumor
Start: 2016-10-19End: 2020-09-30Updated: 2022-10-14
IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
CompletedNCT03568539
Innovent Biologics (Suzhou) Co. Ltd.Advanced/Metastatic Solid Malignancies
Start: 2018-06-27End: 2020-12-07Updated: 2021-06-01

Phase 2

Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment
CompletedNCT03116152
Innovent Biologics (Suzhou) Co. Ltd.Esophageal Squamous Cell Carcinoma
Start: 2017-05-10End: 2019-10-02Updated: 2021-02-03
CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients
NCT03732430
Taizhou HospitalThoracic Malignancies
Start: 2018-11-14End: 2022-05-31Target: 45Updated: 2018-11-29
Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
RecruitingNCT03872661
Sun Yat-sen UniversityLung Cancer Stage III
Start: 2019-03-01End: 2029-12-31Target: 36Updated: 2026-04-21
Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy
NCT04056949
Junling LiExtensive-Stage Small Cell Lung Cancer
Start: 2019-08-05End: 2021-12-31Target: 30Updated: 2019-08-14

Phase 3

A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC
CompletedNCT03150875
Innovent Biologics (Suzhou) Co. Ltd.Non-small Cell Lung Cancer
Start: 2017-09-01End: 2023-02-22Updated: 2023-02-28
The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery
TerminatedNCT04277663
Innovent Biologics (Suzhou) Co. Ltd.Acral Melanoma That Has Been Removed by Surgery
Start: 2020-04-17End: 2023-02-28Updated: 2023-03-09

Related Papers

Anlotinib in combination with docetaxel for advanced nonsmall cell lung cancer after failure of platinum‐based treatment: A phase 1/2 trial
Cancer2025-05-141 citations
Efficacy and Safety of Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (SHARED): Study Protocol of a Prospective, Multi-Center, Single-Arm Phase 2 Trial.
2022-06-179 citations
A study of neoadjuvant sintilimab combined with chemotherapy TP for locally advanced esophageal squamous cell carcinoma (ESCC).
Journal of Clinical Oncology2022-06-014 citations
Sintilimab in Patients with Previously Treated Metastatic Neuroendocrine Neoplasms
The Oncologist2022-04-2116 citations
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2).
2022-02-14100 citations
Abstract CT041: ORIENT-3: A randomized, open-label, phase 3 study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small-cell lung cancer (sqNSCLC)
Cancer Research2021-07-013 citations
Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study.
2020-10-1727 citations
Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial.
2020-08-1451 citations
Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).
Journal of Clinical Oncology2020-05-2024 citations
Phase Ib study of sintilimab in combination with chemotherapy for 1L advanced or metastatic non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology2019-05-2010 citations
Efficacy and safety of sintilimab in combination with XELOX in first-line gastric or gastroesophageal junction carcinoma (GC/GEJC).
Journal of Clinical Oncology2019-05-201 citations
A first-in-human phase 1a trial of sintilimab (IBI308), a monoclonal antibody targeting programmed death-1 (PD-1), in Chinese patients with advanced solid tumors.
Journal of Clinical Oncology2018-05-2020 citations
Dynamic change of PD-L1 expression on circulating tumor cells in advanced gastrointestinal tumor patients undergoing PD-1 blockade therapy.
Journal of Clinical Oncology2018-05-20